VivoSim Labs, INC.
VIVS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VIVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VIVS
VivoSim Labs, INC. (VIVS) is a biotechnology company transitioning from clinical drug development to offering bespoke services using complex human tissue models, with a focus on reducing the cost and risk of bringing therapeutics to market.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for VivoSim Labs, INC..
VivoSim Labs, INC. (VIVS) is a biotechnology company transitioning from clinical drug development to offering bespoke services using complex human tissue models, with a focus on reducing the cost and risk of bringing therapeutics to market.
- VivoSim Labs is shifting its business model from clinical drug development (e.g., FXR314 for IBD) to offering services using new approach methodologies (NAM) for toxicology and drug mechanism elucidation [sec_mda · as of 2026-08-12].
- As of June 30, 2026, the company had cash and cash equivalents of $1.7 million, restricted cash of $0.1 million, and an accumulated deficit of $357.3 million [sec_mda · as of 2026-08-12].
- For the year ended March 31, 2026, the company reported other expense of approximately $2.4 million, primarily due to a $2.7 million loss from a 2026 offering [sec_mda · as of 2026-07-14].
- The company has reduced its full-time selling, general, and administrative staff from an average of five employees in Q2 2024 to three in Q2 2025 [sec_mda · as of 2025-08-12].
- VivoSim Labs plans to offer liver and intestinal toxicology insights using NAM models to pharmaceutical and biotech companies [sec_mda · as of 2026-02-11].
What works
- The company is pivoting to a service-based model using NAM models, which may reduce the significant risk and cost of bringing therapeutics to market for partners [sec_mda · as of 2026-08-12].
- VivoSim Labs has reduced operating expenses, including a 3% decrease in SG&A for Q2 2025 compared to Q2 2024, and a reduction in full-time employees [sec_mda · as of 2025-08-12].
What to weigh
- The company has an accumulated deficit of $357.3 million as of June 30, 2026, and its financial statements are prepared on a going concern basis, indicating substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-12].
- Cash and cash equivalents of $1.7 million as of June 30, 2026, are limited, and the company has historically relied on stock offerings and other financing to fund operations [sec_mda · as of 2026-02-11].
- The company reported no revenue for the latest period (as of June 30, 2026) and a net loss of $1.3 million, with other expenses including a $2.7 million loss from a 2026 offering [sec_mda · as of 2026-07-14].
From the filings
Quoted directly from source documents.
The company is transitioning to a service model using NAM models to reduce drug development risk and cost.
“reduce the significant risk and cost of bringing therapeutics to market through the regulatory process. We also will offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.”
SEC MD&A · August 12, 2026
As of June 30, 2026, the company had $1.7 million cash and an accumulated deficit of $357.3 million.
“As of June 30, 2026, we had cash and cash equivalents of approximately $1.7 million, restricted cash of approximately $0.1 million and an accumulated deficit of $357.3 million.”
SEC MD&A · August 12, 2026
The company reported a $2.4 million other expense for the year ended March 31, 2026, due to a warrant loss.
“Other expense was approximately $2.4 million for the year ended March 31, 2026. Other expense consisted of a $2.7 million loss incurred as a result of the 2026 Offering, due to the fair value of the common stock warrants issued exceeding gross proceeds received.”
SEC MD&A · July 14, 2026
The company plans to offer liver and intestinal toxicology insights using NAM models.
“Going forward, we intend to offer partners liver and intestinal toxicology insights using NAM models.”
SEC MD&A · February 11, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Financial statements prepared on a going concern basis with substantial doubt about ability to continue [sec_mda · as of 2026-08-12].
- Limited cash runway — Cash of $1.7M as of June 30, 2026, with no revenue and ongoing losses [sec_mda · as of 2026-08-12].
- Accumulated deficit — Accumulated deficit of $357.3M as of June 30, 2026, indicating historical losses [sec_mda · as of 2026-08-12].
- Business model transition risk — Pivot from clinical drug development to service model may face execution challenges [sec_mda · as of 2026-08-12].
What to watch
- Progress in securing partnerships for NAM model services, as the company pivots to a service-based revenue model [sec_mda · as of 2026-08-12].
- Cash burn rate and any new financing activities, given the limited cash position of $1.7 million as of June 30, 2026 [sec_mda · as of 2026-08-12].
- Updates on the FXR314 program, which was previously the clinical focus for IBD, and whether it will be advanced or licensed [sec_mda · as of 2024-05-31].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run VivoSim Labs, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VivoSim Labs, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.0 months
OCF -$3M · Net income -$1M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$157K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 36,850 | $53K |
| vanguard capital management llc | 30,742 | $44K |
| goldman sachs group inc | 16,072 | $23K |
| blackrock, inc. | 11,817 | $17K |
| vanguard fiduciary trust co | 7,003 | $10K |
| citigroup inc | 6,504 | $9K |
| larson financial group llc | 166 | $237 |
| albion financial group /ut | 159 | $228 |
| wells fargo & company/mn | 111 | $158 |
| osaic holdings, inc. | 95 | $131 |
Showing top 10 of 20 institutional holders of VivoSim Labs, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.8%
- Days to cover
- 0.8
- Shares short
- 52,788
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VIVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for VivoSim Labs, INC.?
VivoSim Labs, INC. (VIVS) is a biotechnology company transitioning from clinical drug development to offering bespoke services using complex human tissue models, with a focus on reducing the cost and risk of bringing therapeutics to market.
What is VivoSim Labs, INC.'s lead drug candidate?
VivoSim Labs, INC.'s most advanced tracked candidate is fxr314 (Phase 2) for Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD); metabolic function-associated steatohepatitis (MASH).
Who is the CEO of VivoSim Labs, INC.?
Douglas Jay Cohen is the chief executive officer of VivoSim Labs, INC. (VIVS).
Where is VivoSim Labs, INC. headquartered?
VivoSim Labs, INC. (VIVS) is headquartered in San Diego, CA, United States.
What therapeutic areas does VivoSim Labs, INC. focus on?
VivoSim Labs, INC. develops therapies across Immunology, Infectious Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.